Company intelligence / Profile preview
Codiak BioSciences
Cambridge, Massachusetts, United Statescodiakbio.com ↗
- Ownership
- Private
- Employees
- ~102
- Development stage
- Other
01
Overview
Codiak developed a proprietary exosome engineering and manufacturing platform ("engEx") to create targeted exosome therapeutics. Lead programs included exoSTING and exoIL‑12, both reaching early clinical stages. The company demonstrated the ability to engineer exosomes with specific payloads or surface proteins for targeted delivery but did not reach late-stage clinical success before ceasing operations due to bankruptcy.
- Therapeutic areas
- OncologyRare DiseasesNeurologyInfectious Diseases
- Modalities
- Exosome-based therapeutics
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Beyond the preview
Go deeper on Codiak BioSciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Codiak BioSciences.